Tha management of androgen-independent carcinoma of the prostate with infusional chemotherapy

Shahneen Sandhu; Geh Ji; Collis Ch

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2007

Prognostic and Predictive Factors in Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel and Estramustine: A Single Institution Experience

Aristotle Bamias, George Bozas, Nikolaos Antoniou, I. Poulias, Katsifotis Harilaos, Andreas Skolarikos, Dionysios Mitropoulos, Christos Alamanis, G. Alivizatos, Haralambos Deliveliotis, Meletios A Dimopoulos

Article2005

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment

Eleni Efstathiou, George Bozas, A. Kostakopoulos, Efstathios Kastritis, C. Deliveliotis, N. Antoniou, D. Skarlos, C. Papadimitriou, Meletios A Dimopoulos, Aristotelis Bamias

Article2010

MicroRNAs Are Mediators of Androgen Action in Prostate and Muscle

Ramesh Narayanan, Jinmai Jiang, Yuriy Gusev, Amanda Jones, Jeffrey D. Kearbey, Duane D. Miller, Thomas D Schmittgen, James T. Dalton

Article2022

Effects of the intestinal microbiota on prostate cancer treatment by androgen deprivation therapy

Safae Terrisse, Laurence Zitvogel, Guido Guido Kroemer

Article1995

Primary Lymphoma of the Prostate: Good Outcome with Doxorubicin-Based Combination Chemotherapy

Andreas H. Sarris, Meletios A Dimopoulos, William Pugh, Fernando Cabanillas